These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification. Pena Pardo FJ; García Vicente AM; Amo-Salas M; López-Fidalgo JF; Garrido Robles JA; de Ayala Fernández JÁ; Del Saz Saucedo P; Muñoz Pasadas M; Soriano Castrejón A Clin Transl Oncol; 2017 Jan; 19(1):111-118. PubMed ID: 27139696 [TBL] [Abstract][Full Text] [Related]
12. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected. Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848 [TBL] [Abstract][Full Text] [Related]
13. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485 [TBL] [Abstract][Full Text] [Related]
14. García Vicente AM; Delgado-Bolton RC; Amo-Salas M; López-Fidalgo J; Caresia Aróztegui AP; García Garzón JR; Orcajo Rincón J; García Velloso MJ; de Arcocha Torres M; Alvárez Ruíz S; Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1575-1587. PubMed ID: 28550611 [TBL] [Abstract][Full Text] [Related]
15. Whole-body computed tomography as first-line imaging procedure to exclude cancer in patients with neurological suspicion of paraneoplastic syndromes: shall clinical practice adhere to recommendations? Parillo M; Quattrocchi CC; Pilato F; Di Lazzaro V; Beomonte Zobel B Radiography (Lond); 2023 Jan; 29(1):8-13. PubMed ID: 36179410 [TBL] [Abstract][Full Text] [Related]
16. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry. Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896 [TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic autoantibody panels: sensitivity and specificity, a retrospective cohort. Albadareen R; Gronseth G; Goeden M; Sharrock M; Lechtenberg C; Wang Y Int J Neurosci; 2017 Jun; 127(6):531-538. PubMed ID: 27356679 [TBL] [Abstract][Full Text] [Related]
19. Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes. Clapp AJ; Hunt CH; Johnson GB; Peller PJ Clin Nucl Med; 2013 Apr; 38(4):241-7. PubMed ID: 23429394 [TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: experience at a regional oncology centre. Vaidyanathan S; Pennington C; Ng CY; Poon FW; Han S Nucl Med Commun; 2012 Aug; 33(8):872-80. PubMed ID: 22669052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]